2型糖尿病患者的睡眠障碍及其相关健康结局:文献综述
本文综述了2型糖尿病患者中睡眠障碍的患病率及其与健康结局的关联,并探讨治疗睡眠障碍对健康结局的改善程度。检索PubMed至2021年1月,纳入观察性和实验性研究。发现失眠、阻塞性睡眠呼吸暂停和不宁腿综合征在2型糖尿病患者中更常见,且睡眠障碍对血糖控制等健康结局产生负面影响。
要点
- 失眠、阻塞性睡眠呼吸暂停和不宁腿综合征在2型糖尿病患者中患病率较高。
- 睡眠障碍与血糖控制等健康结局恶化相关,如失眠与HbA1c升高相关。
- 针对2型糖尿病患者睡眠障碍治疗的随机对照试验稀少,需加强诊治。
核心结论
- 睡眠障碍在2型糖尿病患者中高度流行,并对健康结局产生负面影响。
- 治疗睡眠障碍可能预防糖尿病进展,应努力诊断和治疗睡眠障碍以改善健康和生活质量。
研究设计与样本
- 文献综述,检索PubMed从建库至2021年1月,纳入观察性和实验性研究。
主要发现
- 失眠患病率为39%(95% CI 34, 44),阻塞性睡眠呼吸暂停为55-86%,不宁腿综合征为8-45%,均高于一般人群。
- 失眠与HbA1c升高相关(2.51 mmol/mol [95% CI 1.1, 4.4];0.23% [95% CI 0.1, 0.4])。
- 横断面和前瞻性研究显示睡眠障碍对至少一个糖尿病领域(尤其是血糖控制)产生负面影响。
关键数值与推荐
- 失眠患病率39%(95% CI 34, 44),阻塞性睡眠呼吸暂停55-86%,不宁腿综合征8-45%。
- 失眠与HbA1c升高2.51 mmol/mol(95% CI 1.1, 4.4)或0.23%(95% CI 0.1, 0.4)相关。
临床怎么用
- 常规治疗如减重、睡眠教育和认知行为疗法似乎能有效改善2型糖尿病患者的睡眠和健康结局。
- 应努力诊断和治疗2型糖尿病患者的睡眠障碍,以改善健康和生活质量。
局限性
- 针对2型糖尿病患者睡眠障碍治疗的随机对照试验稀少,样本量小,有时结论不明确。
- 未报告昼夜节律睡眠-觉醒障碍、中枢性嗜睡障碍或异态睡眠的患病率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sleep disorders are linked to development of type 2 diabetes and increase the risk of developing diabetes complications. Treating sleep disorders might therefore play an important role in the prevention of diabetes progression. However, the detection and treatment of sleep disorders are not part of standardised care for people with type 2 diabetes. To highlight the importance of sleep disorders in people with type 2 diabetes, we provide a review of the literature on the prevalence of sleep disorders in type 2 diabetes and the association between sleep disorders and health outcomes, such as glycaemic control, microvascular and macrovascular complications, depression, mortality and quality of life. Additionally, we examine the extent to which treating sleep disorders in people with type 2 diabetes improves these health outcomes. We performed a literature search in PubMed from inception until January 2021, using search terms for sleep disorders, type 2 diabetes, prevalence, treatment and health outcomes. Both observational and experimental studies were included in the review. We found that insomnia (39% [95% CI 34, 44]), obstructive sleep apnoea (55-86%) and restless legs syndrome (8-45%) were more prevalent in people with type 2 diabetes, compared with the general population. No studies reported prevalence rates for circadian rhythm sleep-wake disorders, central disorders of hypersomnolence or parasomnias. Additionally, several cross-sectional and prospective studies showed that sleep disorders negatively affect health outcomes in at least one diabetes domain, especially glycaemic control. For example, insomnia is associated with increased HbA1c levels (2.51 mmol/mol [95% CI 1.1, 4.4]; 0.23% [95% CI 0.1, 0.4]). Finally, randomised controlled trials that investigate the effect of treating sleep disorders in people with type 2 diabetes are scarce, based on a small number of participants and sometimes inconclusive. Conventional therapies such as weight loss, sleep education and cognitive behavioural therapy seem to be effective in improving sleep and health outcomes in people with type 2 diabetes. We conclude that sleep disorders are highly prevalent in people with type 2 diabetes, negatively affecting health outcomes. Since treatment of the sleep disorder could prevent diabetes progression, efforts should be made to diagnose and treat sleep disorders in type 2 diabetes in order to ultimately improve health and therefore quality of life.
引用
- Schipper SBJ, Van Veen MM, Elders PJM, et al. Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature. Diabetologia. 2021. PMID: 34401953. doi:10.1007/s00125-021-05541-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。